Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001171843-25-003273
Filing Date
2025-05-16
Accepted
2025-05-16 07:50:23
Documents
6
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 6-K f6k_051625.htm 6-K 6544
2 EXHIBIT 99.1 exh_991.htm EX-99.1 384090
3 EXHIBIT 99.2 exh_992.htm EX-99.2 222400
4 EXHIBIT 99.3 exh_993.htm EX-99.3 10029
5 EXHIBIT 99.4 exh_994.htm EX-99.4 9957
6 GRAPHIC logo.jpg GRAPHIC 9902
  Complete submission text file 0001171843-25-003273.txt   647830
Mailing Address SUITE 2400 - 745 THURLOW STREET VANCOUVER A1 V6E 0C5
Business Address SUITE 2400 - 745 THURLOW STREET VANCOUVER A1 V6E 0C5 403-607-2621
XORTX Therapeutics Inc. (Filer) CIK: 0001729214 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-40858 | Film No.: 25956951
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)